A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.

ABSTRACT:

Background & aims

Weight loss in response to sibutramine is highly variable. We assessed the association of specific markers of polymorphisms of candidate alpha2A adrenoreceptor, 5-HT transporter, and GNbeta3 genes and weight loss with sibutramine.

Methods

We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. We measured body weight, body mass index, body composition, gastric emptying, and genetic variation (alpha2A C1291G, 5-HTTLPR, and GNbeta3 C825T genotypes). Analysis of covariance was used to assess treatment effects on and associations of the specific markers of candidate genes with weight loss and body composition.

Results

Sibutram

SUBMITTER: Grudell AB 

PROVIDER: S-EPMC2629484 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature